Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Painkiller gabapentin may shield kidneys during obesity surgery

NCT ID NCT06254183

Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This study looked at whether giving a single dose of gabapentin before laparoscopic sleeve gastrectomy (weight-loss surgery) helps protect kidney function in people with severe obesity. 90 patients with normal kidney function were enrolled. Researchers measured kidney markers like creatinine and two newer biomarkers (NGAL and DKK3) to see if gabapentin reduces the risk of acute kidney injury after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
gabapentin (a pain medication)
What this could lead to
If it works, this could point toward a simple way to reduce kidney injury after weight-loss surgery.
What could go wrong
This is a small, single-center Phase 4 trial with only 90 participants. The results may not apply to all patients or surgeries, and gabapentin can cause side effects like dizziness and drowsiness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

90 people

The number who actually took part.

Started

Dec 2024

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: 18-65 years old. * Participants with severe obesity (BMI ≥40 kg/m², without comorbidities or BMI ≥35 kg/m², in the presence of obesity-related comorbidities). * Preserved kidney function at baseline. * For the randomized surgical cohort (Groups II and III), participants with severe obesity scheduled to undergo laparoscopic sleeve gastrectomy. * For the non-randomized external reference cohort (Group I), participants with severe obesity who did not undergo laparoscopic sleeve gastrectomy during the study period or receive the study intervention. * Both sexes. Exclusion Criteria: * Advanced cancer receiving active treatment. * End-stage renal, hepatic, or cardiopulmonary disease. * Untreated schizophrenia or cognitive impairment. * Use of psychiatric medications, as specified in the study protocol. * Active substance abuse. * Chronic use of gabapentin or known hypersensitivity to gabapentin. * Pregnancy or breastfeeding. * Use of medications that could interfere with the assessed study parameter

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury morbid obesity Obesity obesity disorder Postoperative Complications

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury Bariatric surgery candidate Gabapentin Obesity Obesity (bmi > 35)

Contacts and locations

Locations

  • Mansoura University hospitals

    Al Mansurah, Egypt

  • Tanta University hospitals

    Tanta, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.